About Prime Synthesis

About Us

Prime Synthesis, Inc. was founded in the late 80’s to help meet the challenges of a explosive new area of molecular biology- genomics. Short, synthetic sequences of DNA and RNA called oligonucleotides (oligos) are a key tool for genomics research. The growth projections for the number of oligos needed to support this emerging science seemed astronomical at the time- but have since been far exceeded.
 
We are proud to have supplied oligo synthesis materials to most of the leading research labs over the years. We have followed this exciting market towards the final goals of genomically based diagnostics and therapeutics. Our research and business efforts have emphasized solid supports, a key class of raw material used in oligo synthesis. Our Prime PerformanceTM CPG is a solid support that improves the efficiency of oligo synthesis for both research and production. Our market related growth has enabled us to achieve the economies of scale needed to lower our costs and yours. We are located in Aston, PA, just outside of Philadelphia. Our 30,000 square foot facility houses our research laboratories, production areas, and administrative offices.
 

Focus on Oligo Synthesis

As the oligo synthesis market continues to change, we look forward to changing as well. Our continuous improvement programs have emphasized process refinements and methods to scale-up our custom solid supports for the growing therapeutic oligo market. The recent introduction of our hybCPG™ represents a major breakthrough in oligosynthesis solid supports.
 
However, we also wanted to leverage what we have learned about high efficiency oligo synthesis and make it available to the general oligo research community. To this end, we continue to offer our latest technologies in smaller scales and in customized versions to research laboratories around the world.    Contact us for a quotation on any modified solid support chemistry or special physical properties that you might have a need for.

 

Collaborations

Through collaborations with Drexel University, we have access to an extensive array of the most advanced microscopy and spectroscopy instrumentation, as well as an impressive network of chemistry, materials science, and biomedical consultants.
 
Working closely with SIRNA Pharmaceuticals, Prime Synthesis has optimized its CPG for therapeutic  oligo synthesis. Part of this optimization includes a proprietary linker chemistry, that is currently being  licensed from Alnylam Pharmaceuticals under this agreement.
 
In 2011 we began working on a project with researchers in the Arrhenius Laboratory at the University of Stockholm on a novel biocatalysis product based on our CPG and hybCPGTM solid supports. This new product line, EziG™, has been recently introduced.
 

Funded Research

Early Prime Synthesis research efforts were awarded two rounds of funding from the Ben Franklin Technology Partners Emerging Growth program in both 1992 and 1994.  This work allowed the study of CPG characteristics and nucleoside attachment chemistry  to develop the optimum solid supports for oligonucleotide synthesis and large scale manufacturing capabilities.
 
 In 2009 we were awarded an SBIR Phase I grant from the National Institutes of Health for a project which helped tol define our next generation of oligo synthesis supports: hybCPGTM. This work has resulted in three US patents and a pending  European application.
 
Our hybCPG project was also awarded funds from the Qualifying Therapeutic Discovery Program, as part of the Health Care Reduction Act. Funding was provided for both 2009 and 2010 research expenditures, based on the healthcare cost-saving potential of this work.
 
In 2013 we were awarded a Phase I SBIR Grant from The National Institute of Standards Technology to study the 3-D nanostructural characteristics of hybCPGTM as a nano-tech tool for advanced pharmaceutical maufacturing. This award reflected the NIST comittment to improving the U.S. high tech manufacturing base, through its Manufacturing Extension Program. This work has lead to a pending Phase II proposal to continue the project.
 

Advanced analytical capabilities such as electrospray mass spectrometry are available via collaboration with Integrated DNA Technology.